Showing results (51-60 of 255) with videos related to
Sort By:
Pageof 26
Methods in Molecular Biology (Clifton, N.J.)|February 6, 2014
Pathology of systemic lupus erythematosus: the challenges aheadPedro Correia Azevedo, Grainne Murphy, David A IsenbergRheumatology (Oxford, England)|March 19, 2011
Assessment of a lupus nephritis cohort over a 30-year periodSara C Croca, Teresa Rodrigues, David A IsenbergJournal of Autoimmunity|July 28, 2016
The diagnosis and management of the haematologic manifestations of lupusAlba Velo-García, Sara Guerreiro Castro, David A IsenbergLupus|February 20, 2025
Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapyPedro Gaspar, Prabal Mittal, Hannah Cohen, et al.Lupus Science & Medicine|August 25, 2015
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II studyMurray B Urowitz, David A Isenberg, Daniel J WallaceLupus Science & Medicine|February 2, 2018
Very delayed lupus nephritis: a report of three cases and literature reviewAndré R Alexandre, Pedro L Carreira, David A IsenbergResearch and Practice in Thrombosis and Haemostasis|February 22, 2024
Bleeding events in thrombotic antiphospholipid syndrome: prevalence, severity, and associated damage accrualPedro Gaspar, Prabal Mittal, Hannah Cohen, et al.Rheumatology (Oxford, England)|February 6, 2024
Where are we now in biologic drugs for myositis?Ana Neves, Luísa Viveiros, Veronica Venturelli, et al.Clinical and Experimental Rheumatology|March 25, 2024
A large cohort comparison of very late-onset systemic lupus erythematosus with younger-onset patientsLuisa Viveiros, Ana Neves, Teresa Gouveia, et al.Research and Reports in Urology|July 17, 2023
Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential OpportunitiesAna Neves, Luísa Viveiros, Veronica Venturelli, et al.Pageof 26